Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Potential Buyers Reportedly Interested in Valeant’s OIC Treatment

By Ryan Bushey | August 9, 2016

Valeant Pharmaceuticals is reportedly in early talks to sell Relistor, a tablet for treating opioid-induced constipation.

Talks are in the early stages, according to Bloomberg, but a sale of this drug could help the embattled Canadian company chip away at its staggering $30 billion in debt. Sources told the publication Relistor could be valued between $400 million and $500 million.

Valeant paid an initial $50 million to Progenics Pharmaceuticals last month after the FDA approved the drug to help patients taking an opioid regimen deal with chronic, non-cancer pain. Progenics, a drug-maker that partnered with Valeant on developing the tablet form of Relistor, is entitled to receive an estimated $200 million in milestone payments based on sales of this therapy.

Valeant is hoping that Relistor could pose a threat to AstraZeneca’s similar drug Movantik, reported FiercePharma. An FDA approval helped, but analysts felt that blockbuster revenues aren’t guaranteed. Progenics predicted over $1 billion in peak sales for the pill version of Relistor. Analyst estimates, however, fluctuated between $125 million and $750 million.

Sources explained to Bloomberg Valeant could still back out of this rumored deal although the other assets could also be sold including the firm’s dermatology and pharmaceutical units.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE